150 related articles for article (PubMed ID: 16603533)
1. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
3. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
5. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
[TBL] [Abstract][Full Text] [Related]
6. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
8. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
[TBL] [Abstract][Full Text] [Related]
12. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
[TBL] [Abstract][Full Text] [Related]
13. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
15. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.
Gonzalez LM; Brindeiro RM; Tarin M; Calazans A; Soares MA; Cassol S; Tanuri A
Antimicrob Agents Chemother; 2003 Sep; 47(9):2817-22. PubMed ID: 12936979
[TBL] [Abstract][Full Text] [Related]
16. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Young TP; Parkin NT; Stawiski E; Pilot-Matias T; Trinh R; Kempf DJ; Norton M
Antimicrob Agents Chemother; 2010 Nov; 54(11):4903-6. PubMed ID: 20805393
[TBL] [Abstract][Full Text] [Related]
18. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
[TBL] [Abstract][Full Text] [Related]
19. Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.
Rodés B; Poveda E; Soriano V
J Clin Microbiol; 2002 Nov; 40(11):4313-6. PubMed ID: 12409418
[TBL] [Abstract][Full Text] [Related]
20. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.
Soares EA; Santos AF; Gonzalez LM; Lalonde MS; Tebit DM; Tanuri A; Arts EJ; Soares MA
J Antimicrob Chemother; 2009 Nov; 64(5):938-44. PubMed ID: 19710076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
